255 related articles for article (PubMed ID: 30790095)
21. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
22. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH
Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
[TBL] [Abstract][Full Text] [Related]
24. Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis.
Ogawa N; Ohashi H; Ota Y; Kobori K; Suzuki M; Tsuboi S; Hayakawa M; Goto Y; Karahashi T; Kimoto O; Miyamoto T; Furukawa S; Shimoyama K; Suzuki D; Maekawa Y
Immunol Med; 2019 Mar; 42(1):29-38. PubMed ID: 31067155
[TBL] [Abstract][Full Text] [Related]
25. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
26. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
27. Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis.
Okazaki S; Watanabe R; Harigae H; Fujii H
Tohoku J Exp Med; 2020 Mar; 250(3):153-159. PubMed ID: 32132324
[TBL] [Abstract][Full Text] [Related]
28. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
Alemao E; Johal S; Al MJ; Rutten-van Mölken M
Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
[TBL] [Abstract][Full Text] [Related]
30. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Bjørner JB; Hetland ML
Arthritis Rheumatol; 2019 Dec; 71(12):1997-2004. PubMed ID: 31268624
[TBL] [Abstract][Full Text] [Related]
32. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
Alten R; Nüßlein HG; Mariette X; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
RMD Open; 2017; 3(1):e000345. PubMed ID: 28243468
[TBL] [Abstract][Full Text] [Related]
33. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
Montastruc F; Renoux C; Hudson M; Dell'Aniello S; Simon TA; Suissa S
Semin Arthritis Rheum; 2019 Jun; 48(6):1053-1058. PubMed ID: 30772001
[TBL] [Abstract][Full Text] [Related]
34. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
[TBL] [Abstract][Full Text] [Related]
36. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
37. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N
Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039
[TBL] [Abstract][Full Text] [Related]
38. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
[TBL] [Abstract][Full Text] [Related]
39. RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation.
Dudler J; Tuerk R; Handschin T; Forster A
Swiss Med Wkly; 2013; 143():w13849. PubMed ID: 24318979
[TBL] [Abstract][Full Text] [Related]
40. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
